^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Prolymphocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia
Published date:
07/25/2020
Excerpt:
Our patient, having progressed through standard of care treatments, was trialled on novel treatments including dasatinib, venetoclax and vemurafenib.
DOI:
10.1111/bjh.16992
